New research reveals that the same framework of proteins and peptides that can detect Alzheimer’s disease in cerebrospinal fluid can also detect other forms of neurodegeneration, like frontotemporal degeneration.
Rutgers Biomedical and Health Sciences has opened a new brain imaging research center to improve the diagnosis of neurological and psychiatric disorders and to help personalize and monitor treatments.
The interaction between an individual’s genetics and their local environment plays a critical role in an individual’s likelihood of getting Parkinson’s disease. In this perspective, researchers highlight how a common fly could be used to better understand the complex interactions…
A new University of California, Irvine-led study finds low serum levels of the sugar N-acetylglucosamine (GlcNAc), is associated with progressive disability and neurodegeneration in multiple sclerosis (MS).
DALLAS – April 27, 2021 – Researchers with the Peter O’Donnell Jr. Brain Institute at UT Southwestern have identified a new protein implicated in cell death that provides a potential therapeutic target that could prevent or delay the progress of neurodegenerative diseases following a stroke.
As regenerative therapies for blinding diseases move closer to clinical trials, the National Eye Institute’s functional imaging consortium, a part of the NEI Audacious Goals Initiative (AGI), is pioneering noninvasive technologies to monitor the function of the retina’s light-sensing neurons and their connections to the brain.
Typically characterized as poisonous, corrosive and smelling of rotten eggs, hydrogen sulfide’s reputation may soon get a face-lift thanks to Johns Hopkins Medicine researchers. In experiments in mice, researchers have shown the foul-smelling gas may help protect aging brain cells against Alzheimer’s disease. The discovery of the biochemical reactions that make this possible opens doors to the development of new drugs to combat neurodegenerative disease.
University at Buffalo researchers have received a $957,000 grant from the U.S. Army Medical Research and Development Command to explore the progression of neurodegeneration in multiple sclerosis (MS).
DALLAS – Aug. 12, 2020 – In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease’s characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.
Researchers at Washington University School of Medicine in St. Louis have developed a technique to detect minute amounts of a protein fragment linked to Alzheimer’s disease in the blood. The study, which will be published July 28 in the Journal of Experimental Medicine (JEM), shows that levels of p-tau-217 are elevated during the early stages of Alzheimer’s disease and could lead to a simple blood test capable of diagnosing the neurodegenerative disorder years before any symptoms begin to appear.
Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease.
The article, published in Brain Pathology, describes how SAFB1 expression occurs in both spinocerebellar ataxias and Huntington’s disease and may be a common marker of these conditions, which have a similar genetic background.
After a brain injury, cells that normally nourish nerves may actually kill them instead, a new study in rodents finds. This “reactive” phenomenon may be the driving factor behind neurodegenerative diseases like glaucoma, a leading cause of blindness.
National Eye Institute (NEI) researchers profiling epigenomic changes in light-sensing mouse photoreceptors have a clearer picture of how age-related eye diseases may be linked to age-related changes in the regulation of gene expression. The findings, published online April 21 in Cell Reports, suggest that the epigenome could be targeted as a therapeutic strategy to prevent leading causes of vision loss, such as age-related macular degeneration (AMD).
MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer’s and other neurodegenerative diseases.
Researchers in Japan have identified a new quality control system that allows cells to remove damaged and potentially toxic proteins from their surroundings. The study, which will be published February 18 in the Journal of Cell Biology, finds that the Clusterin protein and heparan sulfate proteoglycans combine to bring misfolded proteins into cells for degradation. The findings may lead to new therapeutic targets for neurodegenerative disorders, including Alzheimer’s disease.
Researchers at Albany Medical College in New York have discovered that a specific type of immune cell accumulates in older brains, and that activating these cells improves the memory of aged mice. The study, which will be published February 5 in the Journal of Experimental Medicine (JEM), suggests that targeting these cells might reduce age-related cognitive decline and combat aging-associated neurodegenerative disease in humans.
Houston Methodist scientists identified a protein found in ovarian cancer that may contribute to declining brain function and Alzheimer’s disease, by combining computational methods and lab research.
An international team of experts led by researchers in the Perelman School of Medicine at the University of Pennsylvania and University of Glasgow has been awarded a $9.7 million, five-year grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute for Aging (NIA) to establish CONNECT-TBI—a program spanning 12 institutions which will study traumatic brain injury (TBI) and related neurodegenerative diseases.